Preliminary HER2 expression data from NeuACT, the phase II randomized, open-label trial of DN24-02 in patients (pts) with surgically resected HER2+ urothelial cancer (UC) at high risk for recurrence.
Michael F. Press
No relevant relationships to disclose
Peter H. O'Donnell
Honoraria - Dendreon (B)
Elizabeth R. Plimack
Research Funding - Dendreon
Other Remuneration - Dendreon
Jean H. Hoffman-Censits
No relevant relationships to disclose
David I. Quinn
Consultant or Advisory Role - Algeta; Amgen; Astellas Pharma; AVEO; Bayer; Dendreon; Fresenius Biotech; Genentech; Medivation; Novartis; Pfizer; Prometheus
Honoraria - Algeta; Amgen; Astellas Pharma; AVEO; Bayer; Dendreon; Fresenius ; Genentech; Medivation; Novartis; Pfizer; Prometheus
Research Funding - Millennium; Sanofi
Expert Testimony - Medivation; Teva
Padmanee Sharma
Consultant or Advisory Role - Bristol-Myers Squibb; Dendreon; Helsinn Therapeutics; Jounce Therapeutics; MedImmune
Todd DeVries
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Melissa Chen
No relevant relationships to disclose
Michael Locker
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Dean F. Bajorin
Consultant or Advisory Role - Dendreon; Lilly; Pfizer
Honoraria - Lilly
Research Funding - Amgen; Dendreon; Genentech; Novartis; Pfizer